Patents by Inventor Jan Geliebter

Jan Geliebter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9597393
    Abstract: The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can be derived from a virus, a cancer, or a diseased cell. The elicited immune response can be cellular, humoral, or both.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: March 21, 2017
    Assignee: AV THERAPEUTICS, INC.
    Inventors: Raj Tiwari, Robert Suriano, Abraham Mittelman, Jan Geliebter
  • Publication number: 20150017202
    Abstract: The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can be derived from a virus, a cancer, or a diseased cell. The elicited immune response can be cellular, humoral, or both.
    Type: Application
    Filed: February 11, 2013
    Publication date: January 15, 2015
    Applicant: AV Theapeutics, Inc.
    Inventors: Raj Tiwari, Robert Suriano, Abraham Mittelman, Jan Geliebter
  • Publication number: 20100316668
    Abstract: The present invention relates to the treatment of prostate cancer. Methods and compositions comprising recombinant BCG are provided for eliciting potent immune responses against prostate specific antigens that are effective for treatment of prostate cancer and metastatic disease.
    Type: Application
    Filed: May 17, 2010
    Publication date: December 16, 2010
    Inventor: Jan Geliebter
  • Patent number: 7718166
    Abstract: The present invention relates to the treatment of prostate cancer. Methods and compositions comprising recombinant BCG are provided for eliciting potent immune responses against prostate specific antigens that are effective for treatment of prostate cancer and metastatic disease.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: May 18, 2010
    Assignee: Applied Immune Technologies
    Inventor: Jan Geliebter
  • Publication number: 20070086982
    Abstract: The present invention is directed towards a method of regulating smooth muscle tone, comprising the introduction, into smooth muscle cells of a subject, of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. Specifically, the invention provides methods of gene therapy for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. The present invention also provides recombinant viral and non-viral vectors comprising DNA encoding a protein involved in the regulation of smooth muscle tone. Further provided by the present invention is a smooth muscle cell which expresses a gene encoding a protein involved in the regulation of smooth muscle tone.
    Type: Application
    Filed: December 1, 2005
    Publication date: April 19, 2007
    Inventors: Jan Geliebter, George Christ, Arnold Melman, Jamil Rehman
  • Patent number: 7030096
    Abstract: The present invention is directed towards a method of regulating smooth muscle tone, comprising the introduction, into smooth muscle cells of a subject, of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. Specifically, the invention provides methods of gene therapy for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. The present invention also provides recombinant viral and non-viral vectors comprising DNA encoding a protein involved in the regulation of smooth muscle tone. Further provided by the present invention is a smooth muscle cell which expresses a gene encoding a protein involved in the regulation of smooth muscle tone.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: April 18, 2006
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Jan Geliebter, George J. Christ, Arnold Melman, Jamil Rehman
  • Publication number: 20040022770
    Abstract: The present invention relates to the treatment of prostate cancer. Methods and compositions comprising recombinant BCG are provided for eliciting potent immune responses against prostate specific antigens that are effective for treatment of prostate cancer and metastatic disease.
    Type: Application
    Filed: March 3, 2003
    Publication date: February 5, 2004
    Inventor: Jan Geliebter
  • Patent number: 6150338
    Abstract: The present invention is directed towards gene therapy for erectile dysfunction through delivery and expression of a recombinant vector containing a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a smooth muscle cell. Also provided by the present invention is a method of inducing penile erection in a subject comprising the introduction and expression of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a sufficient number of cells of the subject to induce penile erection in the subject. The present invention also provides a recombinant vector comprising the DNA of or corresponding to at least a portion of the genome of a virus, which portion is capable of directing the expression of a DNA sequence, and DNA encoding a protein involved in the regulation of smooth muscle tone operably linked to the viral DNA and capable of being expressed as a functional gene product in the target cell.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 21, 2000
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Jan Geliebter, Arnold Melman, George J. Christ, Jamil Rehman
  • Patent number: 5925682
    Abstract: A method for reducing cancerous tumors is disclosed. The method includes administering to a mammal an effective amount of epinephrine. In another embodiment, the mammal is immediately immobilized after receiving injections of epinephrine. In a most preferred embodiment, the method also includes administering an effective amount of a cardioselective adrenergic blocking agent prior to administering of epinephrine.
    Type: Grant
    Filed: November 18, 1996
    Date of Patent: July 20, 1999
    Assignee: Immunotech Inc.
    Inventors: Paul K. Gruber, Jan Geliebter